18:50:07 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandFinland
ListaFirst North Finland
SektorHälsovård
IndustriMedicinteknik
BBS-Bioactive Bone Substitutes är verksamma inom medicinteknik. Bolaget designar, utvecklar och konstruerar biologiska implantat för patienter med benfel och läkningsbesvär. Bolagets lösningar vidaresäljs under varumärket Artebone och baseras på tricalciumfosfat (TCP) och benprotein, som stimulerar benläkningsprocessen. Bolaget grundades under 2003 och har sitt huvudkontor i Oulu.

Kalender

2023-03-23 Bokslutskommuniké 2022
2022-08-25 Kvartalsrapport 2022-Q2
2022-04-29 Ordinarie utdelning BONEH 0.00 EUR
2022-04-28 Årsstämma 2022
2022-03-17 Extra Bolagsstämma 2022
2022-02-24 Bokslutskommuniké 2021
2021-08-25 Kvartalsrapport 2021-Q2
2021-04-29 Ordinarie utdelning BONEH 0.00 EUR
2021-04-28 Årsstämma 2021
2021-02-24 Bokslutskommuniké 2020
2020-08-31 Kvartalsrapport 2020-Q2
2020-04-06 Ordinarie utdelning BONEH 0.00 EUR
2020-04-05 Årsstämma 2020
2020-03-20 Bokslutskommuniké 2019
2019-08-30 Kvartalsrapport 2019-Q2
2019-04-08 Ordinarie utdelning BONEH 0.00 EUR
2019-04-05 Årsstämma 2019
2018-08-30 Kvartalsrapport 2018-Q2
2018-03-29 Årsstämma 2018
2022-03-29 15:30:00

Company release 29th March 2022, 4:30 PM

 

BBS Oyj’s Annual Report for 2021 has been published 29.3.2022. The Publication is attached to this release and can be found at https://www.bbs-artebone.fi/investors/financial-reports/ 

The Publication includes the English translation of the Annual Report and the Audited Financial Statements for 2021. The English translation of the Financial Statements for Financial Year 2021 is also available on company’s website at https://www.bbs-artebone.fi/investors/financial-reports/
 
More information: 
Ilkka Kangasniemi, CEO 
ilkka.kangasniemi@bbs-artebone.fi
+358 40 7080307 


Distribution: 
Nasdaq Helsinki Oy 
Nasdaq Stockholm AB
Main Media 
www.bbs-artebone.fi


BBS – Bioactive Bone Substitutes Plc 
BBS-Bioactive Bone Substitutes Plc is a Finnish orthobiologic biotech company. We have developed a new product for healing of difficult bone fractures and for solving the problems in bone healing. Our mission is to offer new generation medicinal products for the orthopedic 
surgery. The research and development in the field of medicine requires perseverance and courage to develop new things. We have over 20 years of expertise in this. Our operations are haracterised by top expertise, innovativeness and dedicated and committed employees. The 
first product, ARTEBONE® paste, is ready and the application process for the CE-marking enabling commercialization is in progress. 


More information: www.bbs-artebone.fi 
BBS-Bioactive Bone Substitutes Plc shares are listed on the Nasdaq First North Growth Market.